{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T03:13:10Z","timestamp":1761966790797,"version":"build-2065373602"},"reference-count":26,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,8,5]],"date-time":"2011-08-05T00:00:00Z","timestamp":1312502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:p><jats:bold>Background:\u2002<\/jats:bold> Rasagiline, an MAO\u2010B inhibitor, is indicated for the treatment of Parkinson\u2019s disease (PD). In this <jats:italic>post hoc<\/jats:italic> analysis, the efficacy, safety and tolerability of rasagiline as an adjunct to levodopa were compared with placebo in elderly (\u226570\u2003years) and younger (&lt;70\u2003years) patients with PD.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Data were pooled from the Parkinson\u2019s Rasagiline: Efficacy and Safety on the Treatment of \u2018OFF\u2019 and Lasting effect in Adjunct therapy with Rasagiline Given Once daily randomized, double\u2010blind, placebo\u2010controlled trials with the primary efficacy end\u2010point being the reduction from baseline in daily OFF time. Secondary efficacy end\u2010points included scores for Clinical Global Improvement (CGI)\u2010Examiner during ON time, Unified Parkinson\u2019s Disease Rating Scale (UPDRS)\u2010ADL during OFF time, UPDRS\u2010Motor during ON time and total daily ON time with and without troublesome dyskinesia. Tolerability was evaluated from adverse events (AEs) in the two age groups.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Rasagiline decreased daily OFF time versus placebo (<jats:italic>P\u2003<\/jats:italic>&lt;<jats:italic>\u2003<\/jats:italic>0.01) and improved CGI\u2010Examiner score (<jats:italic>P\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.001) and UPDRS\u2010Motor ON score (<jats:italic>P\u2003<\/jats:italic>&lt;<jats:italic>\u2003<\/jats:italic>0.05). Changes in UPDRS\u2010ADL OFF score and total daily ON time without dyskinesia also favoured rasagiline but were not significant. Between\u2010group comparisons (\u226570 vs. &lt;70\u2003years) showed that efficacy was unaffected by age for all end\u2010points (<jats:italic>P\u2003<\/jats:italic>&gt;<jats:italic>\u2003<\/jats:italic>0.1), and rasagiline was well tolerated amongst both groups of patients with a comparable incidence of total and dopaminergic AEs (<jats:italic>P\u2003<\/jats:italic>&gt;<jats:italic>\u2003<\/jats:italic>0.1).<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Adjunct rasagiline is efficacious and well tolerated in elderly non\u2010demented patients (\u226570\u2003years) with moderate to advanced PD. Confirmation of the efficacy and safety of rasagiline in the elderly patient subgroup is especially relevant because of the increasing number of elderly patients with PD.<\/jats:p>","DOI":"10.1111\/j.1468-1331.2011.03484.x","type":"journal-article","created":{"date-parts":[[2011,8,5]],"date-time":"2011-08-05T12:31:58Z","timestamp":1312547518000},"page":"258-264","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson\u2019s disease"],"prefix":"10.1111","volume":"19","author":[{"given":"E.","family":"Tolosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. B.","family":"Stern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,8,5]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"31","volume-title":"Monoamine Oxidase Inhibitors \u2013 The State of the Art","author":"Finberg JPM","year":"1981"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200011000-00005"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.59.12.1937"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809335"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.2.241"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71083-7"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.3_Suppl_3.S1"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.suppl_5.S1"},{"issue":"5","key":"e_1_2_7_10_2","first-page":"S21","article-title":"Prevalence of Parkinson\u2019s disease in Europe: a collaborative study of population\u2010based cohorts","volume":"11","author":"de Rijk MC","year":"2000","journal-title":"Neurology"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000210692.95595.1c"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.17.5.427"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200003000-00003"},{"volume-title":"028 CGI. Clinical Global Impressions","year":"1976","author":"National Institute for Mental Health","key":"e_1_2_7_14_2"},{"volume-title":"Unified Parkinson\u2019s Disease Rating Scale (UPDRS)","year":"1987","author":"Fahn S","key":"e_1_2_7_15_2"},{"issue":"2","key":"e_1_2_7_16_2","first-page":"95","article-title":"PRESTO and LARGO: once\u2010daily rasagiline produces consistent treatment benefits in US and European studies of Parkinson\u2019s disease patients","volume":"13","author":"Schwid S","year":"2006","journal-title":"Eur J Neurol"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410420511"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.1.162"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.4.1057"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70108-4"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.4.1066"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.3.665"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.5.1309"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200007)15:4<664::AID-MDS1010>3.0.CO;2-D"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000215250.82576.87"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01548.x"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20036"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1331.2011.03484.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1331.2011.03484.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T18:02:47Z","timestamp":1698688967000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1331.2011.03484.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,5]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.1111\/j.1468-1331.2011.03484.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1331.2011.03484.x","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"type":"print","value":"1351-5101"},{"type":"electronic","value":"1468-1331"}],"subject":[],"published":{"date-parts":[[2011,8,5]]},"assertion":[{"value":"2011-08-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}